Buy or sell HeartFlow stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
HeartFlow Stock
Medical Technology Company
About HeartFlow Stock
HeartFlow is a medical technology company that provides non-invasive coronary artery disease detection services. The company's main product is HeartFlow FFRCT Analysis, which aims to help a physician evaluate whether a patient has significant coronary artery disease. HeartFlow FFRCT Analysis uses a CT scan that is ordered by a physician to generated a 3D model of the patient's coronary arteries. The analysis aims to calculate the amount of blockage in the arteries and the limited blood flow. The HeartFlow FFRCT Analysis is commercially available in the United States, Canada, Europe and Japan.
The company additionally offers HeartFlow Planner which allows physicians to model treatment strategies for coronary artery disease.
The company is currently operating with business as usual, albeit with smaller, isolated teams. HeartFlow is allowing for hospitals to divert resources toward COVID-19 by letting algorithms replace invasive procedures like angiograms.
Christopher K. Zarins and Charles Anthony Taylor founded Cardiovascular Simulation in 2007 that became HeartFlow in May 2009. The company is headquartered in Redwood City, California. For more information, visit www.heartflow.com.
Investors
Baillie Gifford
Flipkart, Ola, Spotify, goPuff, Indigo, Ginkgo Bioworks, Tempus, Scopely, Zymergen, Joby Aviation
Capricorn Investment Group
QuantumScape, HeartFlow, Innovium, Diamond Foundry, Kinestral Technologies
LifeForce Capital
HeartFlow, Cityblock Health, One Medical, Clover Health, Vineti, Verge Genomics
Martis Capital
Rancilio Cube
Wellington Management
Swiggy, Scopely, Attentive, HeartFlow, Cityblock Health, Harry's, ACV, ezCater, Omada Health, nCino
Funding History
| July 2009 | $2.0M |
|---|---|
| August 2010 | $6.9M |
| August 2010 | $10.1M |
| December 2011 | $105M |
| January 2015 | $111M |
| November 2017 | $340M |
Management
Chief Executive Officer
John Stevens
Chief Technology Officer
Charles Anthony Taylor
Press
MobiHealthNews - Apr, 7 2021
BusinessWire - Apr, 6 2021
neurons - Feb, 16 2021
BioWorld - Jan, 31 2020
techradar - Dec, 10 2019
Medical Device - Oct, 24 2019
businesswire - Sep, 12 2019
massdevice - Jun, 17 2019
bioportfolio - May, 23 2019
computerworlduk - Feb, 21 2019
massdevice - Feb, 8 2019
3ders.org (blog) - Feb, 16 2018
Mass Device - Dec, 5 2017
fiercemedicaldevices - Feb, 13 2015
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from HeartFlow or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
